3 “Strong Buy” Biotech Stocks – Week of 11/26

Biotech stocks have been a hot topic in the investment world for several years now. With advancements in technology and an increased focus on healthcare, the biotech industry has experienced significant growth and innovation. As a result, many investors are turning to biotech stocks as a way to diversify their portfolio and potentially earn significant returns.

Here are three “Strong Buy” Biotech stocks from Wall Street –

NewAmsterdam Pharma Company N.V. – SYM: NAMS
Recent Price: $9.80
Price Target: $25.00
Firms with Buy Rating: Jefferies, RBC Capital, Credit Suisse
Description: NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).

Your new “Quick Response” bank account

qr code

The Federal government could soon mail you a private QR code. It’ll be your passport to a new financial system… as important as your bank account or social security number. It’s the biggest change to money in America in decades…

And it’s crucial you understand how it’ll impact you ASAP.


Legend Biotech Corporation – SYM: LEGN
Recent Price: $59.98
Price Target: $91.26
Firms with Buy Rating: Citi, Jefferies, Goldman Sachs
Description: Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia , gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.


Sarepta Therapeutics, Inc. – SYM: SRPT
Recent Price: $83.44
Price Target: $129.75
Firms with Buy Rating: J.P. Morgan, Barclays, Needham
Description: Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.